Earnings Summary

Castle Biosciences Inc’s revenue jumped 72.47% since last year same period to $66.12Mn in the Q4 2023. On a quarterly growth basis, Castle Biosciences Inc has generated 7.52% jump in its revenue since last 3-months.

Castle Biosciences Inc’s net profit jumped 87.49% since last year same period to $-2.58Mn in the Q4 2023. On a quarterly growth basis, Castle Biosciences Inc has generated 62.64% jump in its net profits since last 3-months.

Castle Biosciences Inc’s net profit margin jumped 92.74% since last year same period to -3.9% in the Q4 2023. On a quarterly growth basis, Castle Biosciences Inc has generated 65.25% jump in its net profit margins since last 3-months.

Castle Biosciences Inc’s earning per share (EPS) estimates for the current quarter stand at -0.32 - a 40.74% jump from last quarter’s estimates.

Castle Biosciences Inc’s earning per share (EPS) estimates for the current year stand at -0.32.

Castle Biosciences Inc’s earning per share (EPS) jumped 87.18% since last year same period to -0.1 in the Q4 2023. This indicates that the Castle Biosciences Inc has generated 87.18% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Castle Biosciences Inc’s return on assets (ROA) stands at -0.09.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Castle Biosciences Inc’s return on equity (ROE) stands at -0.15.